Factor | Biological function | Source | Ref |
---|---|---|---|
Vascular endothelial growth factor (VEGF) | Wound healing | Amnio-M | |
Platelet-derived growth factor (PDGF) | Pro-angiogenic activity | [5] | |
\(\alpha\) 1 anti-trypsin | Protease inhibitors suppress the IL-1-mediated inflammation | [93] | |
Inter-\(\alpha\) -trypsin inhibitor | |||
IL-1 inhibitors (IL-1RA) | |||
Fibroblast growth factor 6 (FGF-6) | Increase regeneration potential, Induce HUVEC cell migration | Amnio-M secretome | [6] |
Platelet-derived growth factor AB (PDGF-AB) | |||
Macrophage colony-stimulating factor receptor (M-CSFR) | |||
Vascular endothelial growth factor receptor 3 (VEGFR3) | |||
Neurotrophin-4 (NT-4) | |||
Insulin-like growth factor-binding protein 4 (IGFBP-4) | |||
Insulin-like growth factor-binding protein 6 (IGFBP-6) | |||
Elafin | Antibacterial effect | Â | [109] |
Secretory leukocyte protease inhibitor (SLPI) | Anti-inflammatory | Â | |
Interleukin 10 (IL-10) | |||
Endostatin | Anti-angiogenic | Â | [103] |
Tissue inhibitors of metalloproteases (TIMP-1, 2, 3, 4) | |||
Thrombospondin -1 | |||
Human β-Defensin 2, 3 | Antibacterial effect |  | [109] |
Cathelicidic LL-37 | |||
Collagen XVIII | Anti-angiogenic | AMCs and AECs | [102] |
Hyaluronic acid (HA) | Anti-fibrotic | Amnio-M matrix | [91] |
Fibronectin | Activation of the ERK pathway | Â | [105] |
AECs-derived exosomes | Anti-fibrotic | AECs secretome | [96] |